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Excitatory Armno Acid Binding Sites 
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Leon S. Dure IV, MD, Anne B. Young, MD, PhD, and John B. Penney, MD 
Huntington’s disease is a dominantly inherited, progressive neurodegenerative disorder causing marked pathology in 
the basal ganglia. The pathophysiology of the selective neuronal death is as yet unknown, but evidence suggests that 
the neurotoxicity may result from endogenous substances acting at excitatory amino acid receptors. Previous data 
have shown a selective decrease in binding to one class of glutamate receptors, the N-methyh-aspartate (NMDA) 
receptor in the putamen of Huntington’s disease. The present study was undertaken to determine the relative density 
of binding to all of the currently defined subpopulations of excitatory amino acid receptors in the caudate nuclei and 
frontal cortex of patients with Huntington’s disease and of control subjects, using quantitative in vitro autoradiogra- 
phy. NMDA, MK-801, glycine, kainate, and cr-amino-3-hydroxy-5-methylisoxazole propionic acid (AMPA) receptor 
binding were all decreased to a similar extent (50-60%). Binding to the metabotropic quisqualate receptor and to the 
non-NMDA, nonkainate, nonquisqualate (NNKQ) site was decreased nonsignificantly by 3 1 % arid 26%, respectively. 
Autoradiograms of NMDA, MK-80 1, AMPA, kainate, metabotropic, and NNKQ receptors in caudates revealed an 
inhomogeneous pattern of binding that is different from the binding pattern seen in control caudates. Binding to all 
receptor subtypes was the same in the frontal cortex from Huntington’s disease patients and control subjects. The data 
suggest that no single excitatory amino acid receptor is selectively decreased in the caudate of Huntington’s disease. 
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Huntington’s disease (HD) is a dominantly inherited 
neurodegenerative disorder with complete penetrance, 
onset usually in midlife, adventitious movements, pro- 
gressive dementia, and premature death 11). Behav- 
ioral disturbances may precede or accompany the ill- 
ness. The HD gene is located on the short arm of 
chromosome 4,  but the gene product and its relation 
to the pathophysiology of HD are as yet unknown. 
Pathologically, caudate atrophy due to a loss of 
medium-sized spiny neurons is the hallmark of HD, 
with less marked neuronal loss in the putamen 12, 31. 
Cortical neuronal loss has also been described 14). Stri- 
atal cell loss is not uniform; there is a dramatic loss 
of medium spiny neurons and preservation of small 
aspiny neurons containing neuropeptide Y and so- 
matostatin, as well as the large cholinergic aspiny neu- 
rons [ S ] .  
To explain the pattern of neuronal cell loss in HD, 
a hypothesis has been put forward involving the neuro- 
toxicity of excitatory amino acid (EAA) neurotransmit- 
ters. These neurotransmitters, including glutamate and 
possibly aspartate, are the primary afferent transmitters 
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to the striatum from the cortex {6]. EAA neurotoxicity 
is thought to play a role in hypoxia-ischemia 177, do- 
moic acid-induced encephalopathy IS], and lathyrism 
[9, 10). Experimental evidence suggests that the patho- 
physiology of HD could be due to EAA excitotoxicity 
[ll-181. In the rat and monkey, administration of 
EAA agonists produces a lesion that is pathologically 
and immunohistochemically similar to that found in 
HD, with selective loss of medium-sized spiny neurons 
and sparing of somatostatin, neuropeptide Y, and cho- 
linergic interneurons 118, 191. Fibers of passage within 
the caudate are unaffected. 
EAA receptors are defined pharmacologically as ei- 
ther N-methybaspartate (NMDA) or non-NMDA 
receptors, depending on their affinity for NMDA C20). 
Two other binding sites associated with the NMDA 
receptor complex are the strychnine-insensitive glycine 
site, and the phencyclidine (PCP) receptor 12 1). The 
non-NMDA receptors are further subdivided into 
ionotropic quisqualate receptors, also known as the 
c~-amino-3-hydroxy-5-methylisoxazole propionic acid 
(AMPA) receptors, metabotropic quisqualate recep- 
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tors (associated with phosphoinositide metabolism), 
and kainate receptors 120, 22-24].  Finally, a site that 
has been identified pharmacologically represents the 
specific binding of glutamate in the presence of satura- 
ble concentrations of NMDA, quisqualate, and kai- 
nate. This non-NMDA-, nonkainate-, nonquisqualate- 
sensitive (NNKQ) site is as yet physiologically 
uncharacterized 1251. 
In HD, there is a decrease in total [3H1glutamate 
binding 126, 271. Using more specific assays for gluta- 
mate receptor subpopulations, Young and colleagues 
determined the densities of total glutamate, NMDA- 
sensitive, and quisqualate-sensitive receptor binding in 
putamen from patients with HD,  using quantitative 
in vitro receptor autoradiography [28 ] .  The authors 
found a decrease in receptor binding to both the 
NMDA and non-NMDA receptors in HD, compared 
to control specimens. Of significance was the finding 
that NMDA receptor binding was decreased by more 
than 90%, while both non-NMDA receptor binding 
and total glutamate binding were decreased by 67%. 
The latter decreases were commensurate with the de- 
cline in binding seen in this same study for musca- 
rinic cholinergic receptors, gamma-aminobutyric acid 
A (GABA,) receptors, and benzodiazepine receptors. 
The finding of selective depletion of NMDA receptors 
was considered consistent with the hypothesis that 
NMDA receptor-mediated glutamate excitotoxicity 
plays a role in the pathogenesis of HD. 
The purpose of the present study was to further 
characterize the changes in glutamate receptor popula- 
tions in HD caudate and frontal cortex using more 
recently developed quantitative in vitro receptor auto- 
radiographic binding assays specific for the NMDA, 
AMPA, kainate, metabotropic, and NNKQ receptors. 
Additionally, the strychnine-insensitive glycine site and 
PCP site were studied in both HD and control spec- 
imens. 
Materials and Methods 
Tisszle 
Blocks of tissue containing either caudate nucleus or frontal 
cortex from HD and control brains were selected from the 
University of Michigan Brain Bank, and coded (by J. B. P.) 
for analysis (Table 1). HD brains were pathologically graded 
by the criteria of Vonsattel and colleagues 12). The mean age 
at the time of death (+ standard deviation [SD]) for the 
patients with HD was 50 + 21 (range, 11-88) years, and for 
the control subjects, 60 ? 21 (range, 22-87) years. The 
postmortem delay (+- SD) for the patients and control sub- 
jects was 15 +- 6 (range, 6-24) hours and 16 f 7 (range, 
4-23) hours, respectively. The tissue blocks were kept fro- 
zen at -70°C until they were thawed to -20°C for sec- 
tioning. 
For each receptor assay, blocks were cut into 20-pm-thick 
sections and thaw-mounted onto triple-submerged gelatin- 
coated slides. Slides were stored at - 20°C for no longer than 
48 hours prior to receptor autoradiography. 
Table 1. Charactmitics of Control 
and Hantington's Disease (HD) Brains 
~~ ~~ 
Postmortem 
Disease Mean Age Delay * SD 
Brain Type Gradea ? SD (yr) (hr)b 
Control (n = 12) NIA 60 +- 21 16 * 7 
2 (n = 5) 
4 ( n  = 4)  
68 f 16 
25 +- 5 
HD (n =- 14) 3 (n = 5 )  59 f 5 15 * 6 
'Pathological grade according to the criteria of Vonsatrel and col- 
leagues 127. 
'Denotes the time from death of the patient until the time the brain 
tissue was frozen at - 70°C. 
NIA = not applicable. 
Owing to the scarcity of tissue, not all assays could be done 
in every brain. A total of 14 HD brains and 12 control brains 
were used for assays of the caudate nucleus. The NNKQ 
assay was performed on 4 HD and 7 control caudate nuclei. 
Six  HD and 4 control brains were used for the assays in 
frontal cortex. 
Receptor Assays 
Tritiated glutamate, glycine, and kainate were obtained 
from Amersham (Arlington Heights, IL), and C3H}Ah.IPA 
and r3HIMK-801 were obtained from Dupont, New En- 
gland Nuclear (Boston, MA). 3-(( ?)-2-Carboxypiperazin- 
4-yl)-propyl-l-phosphonic acid (CPP), quisqualic acid, and 
NMDA were purchased from Cambridge Research Bio- 
chemicals (Cambridge, UK), and MK-801 was a generous 
gift from Dr L. L. Iversen of Merck, Sharp & Dohme Re- 
search Lab (Essex, UK). AMPA was obtained from Research 
Biochemicals (Natick, MA). All other reagents for buffers 
were manufactured by Sigma Chemical (St Louis, MO). 
The buffers and incubation conditions for each assay are 
listed in Table 2. For NMDA, AMPA, glycine, metabotropic, 
NNKQ site, and kainate binding, assays were performed by 
prewashing the slides in buffer at 4°C for 30 minutes, then 
air-drying them prior to incubation. Incubations were per- 
formed at 4°C for 45 minutes (with the exception of glycine 
receptor binding, which required a 30-minute incubation), 
followed by a rapid rinse with four 4-ml aliquots of buffer, 
and two 2-ml aliquots of 2.5% glutaraldehyde in acetone. 
The slides were dried rapidly under hot air (10 to 12 seconds 
for each slide). 
PCP receptor binding was measured with the ligand 
[jHIMK-801, and required a prewash of 30 minutes at 4"C, 
an incubation of 120 minutes at room temperature, and a 
rinse time of 80 minutes at 4°C. These slides were not rinsed 
with glutaraldehyde/acetone. 
After each assay, slides were apposed to H~perf i lm-~H 
(Amersham) in x-ray cassettes along with standards of known 
radioactivity. Exposure time varied from 3 to 8 weeks. When 
exposure was completed, films were developed in D-19 
(Eastman Kodak, Rochester, NY), fixed and dried, and the 
resulting images were quantified with respect to radioactive 
binding [29,30} using a computer-based video image analysis 
system (Imaging Research, St Catherines, Ontario, Canada). 
To obtain an average value for binding throughout the area 
of interest (caudate or cortical mantle), the entire structure 
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Table 2 .  Exciiatom Amino Acid Recebtor Assay Conditions 
~~ 
Receptor Buffer 
NMDA 50 mM Tris-acetate 
Glycine 50 mM Trissitrare 
PCP 50 mM Tris-acetate 
AMPA 50 mM Tris-C1, 
2.5 mM CaCl,, 
30 mM KSCN 
Kainate 50 mM Tris-acetate 
Metabotropic 50 mM Tris-CI, 
2.5 mM CaCI,, 
30 mM KSCN 
2.5 mM CaC1, 
NNKQ 50 mM Tris-C1, 
Incubation 
Temperature Time (min) Binding Conditions 
4°C 45 45 nM [3H]glutamate, 
2.5 pM quisqualate, 
1 pM kainate 
4°C 30 100 nM C3H]glycine 
25°C 120 10 nM C3H)MK-801 
4°C 45 37 nM E3H}AMPA 
4°C 45 60 nM C3H)kainate 
4°C 45 82 nM [3H}glutamate, 
100 pM NMDA, 
10 pM AMPA 
4°C 45 82 nM E3H}glutamate, 
100 pM NMDA, 
2.5 FM quisqualate, 




100 pM CPP 
1 mM glycine 
10 pM MK-801 
1 mM glutamate 
100 pM kainate 
2.5 pM quisqualate 
1 mM glutamate 
NMDA = N-methyl-D-asparrate; PCP = phencyclidine; AMPA = a-amino-3-hydroxy-5-rnethylisoxazole propionic acid; NNKQ = non- 
NMDA-, nonkainate-, nonquisqualate-sensitive site; KSCN = potassium thiocyanate; CPP = 3-(( +-)-2-carboxypiperazin-4-yl)-propyl- 1-
phosphonic acid 
was included. Specific binding for each assay was calculated 
by subtracting nonspecific binding density from the value 
obtained for total binding, and is expressed in femtomoles 
per milligram of protein. Triplicate sections were used for 
both total and nonspecific binding. Statistical analysis was 
performed using the StatView 11 software package (Abacus 
Concepts, Berkeley, CA). 
Results 
Excitato y Amino Acid Receptor Subtypes 
i n  Frontal Cortex 
Densitometry readings in the frontal cortex were done 
by sampling the entire cortical mantle. Comparison of 
binding between HD (n = 6) and control specimens 
(n = 4 )  revealed no  significant difference for NMDA,  
glycine, MK-80 1, AMPA, metabotropic quisqualate, 
or kainate receptors (Student’s t test, p > 0.2) (Fig 1). 
Binding to the N N K Q  site was not determined in the 
frontal cortex. 
By using regression analysis, no  significant correla- 
tion with respect to either age or postmortem delay 
could be made for binding in any assay. This lack of 
correlation was u u e  for both HD and control groups. 
Excitato y Amino Acid Receptor Subtypes 
in Caudate Nucleus 
Autoradiograms of EAA receptor binding in control 
human caudate revealed rather homogeneous binding 
in all assays, but this was not the case in the HD cau- 
date (Figs 2 and 3). In  the NMDA, AMPA, MK-801, 
kainate, metabotropic, and N N K Q  assays, the binding 
in the HD caudate was nonuniform. To avoid sampling 
bias, data from large areas of the HD caudate were 
averaged, irrespective of inhomogeneities. 




NMDA GLY MK-807 AMPA* KA METAB 
RECEPTOR TYPE 
F i g  1. Comparison of ligand binding for the different assays in 
frontal cortex in control specimens (solid bars) and Hunting- 
ton’s disease (HD) specimens (hatched bars). Specific binding is 
expressed as femtomoles per milligram of  protein. The asterisk 
&notes AMPA binding expressed as lo-’ fmolfmg ofprotein. 
N M D A  = N-methyl-paspartate: GLY = gl‘ycine; A M P A  = 
a-amino-3-hydroxy-5-methyli~oxazole propionic acid; KA = 
kainic acid; METAB = metabotropic. 
Figure 4 demonstrates the decrease in binding for 
all receptor types in HD caudate compared to control 
specimens. The  decrease in binding was statistically sig- 
nificant for NMDA (51%), glycine (54%), MK-801 
(55%), AMPA (61%), and kainate (55%) assays (un- 
paired, two-tailed Student’s t test; p < 0.005). Binding 
to the metabotropic receptor and the N N K Q  site was 
decreased (31% and 26%, respectively) but not sig- 
nificantly (p > 0.1 for the metabotropic receptor, p > 
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Fig 2. Autoradiogram of N M D A  and the related phencyclictine 
(PCP) receptor binding in  control and Huntington's disease 
(HDi caudate. NMDA-sensitive t3 H)glutamate binding is 
shown in control (A), H D  grade 2 (C),  and H D  grade 4 (E). 
Data from the entire area of the caudzte nucleus were averaged 
to determine the density of binding. Binding to the ion-channel 
PCP site with {?H}MK-801 is seen in control IB), H D  grade 
2 (D),  and H D  grade 4 ( F j  specimens. Inhomogeneous N M D A -  
sensitive {3H}gbtamute binding is especiallr apparent in grade 
4 H D  caudzte (E) .  
Fig 3. Binding to the non-NMDA receptors in  control and 
Huntingtonk disease (HD) caudate is shown by pasqualate- 
sensitive {sHj~-anzino-3-hydroxy-5-metbylisoxazole propionic 
ac-id (AMPA)  (A? C, and E) and (3H}&inde (B, D. dnd Fj 
binding. Controls (A and B),  grade 2 H D  (C and D),  and 
grade 4 N D  (E and F) are illustrated. 
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considered as a parametric variable in a multiple regres- 
sion analysis. With this analysis, there was no consistent 
contribution of grade to the amount of binding. 
. CONTROLCAUDATE T HDCAUDATE 
NMDA GLV MK-801 AMPA* KA METAB NNKQ 
RECEPTOR TYPE 
Fig 4. Comparison of ligand binding as determined by the dzy- 
ferent assays in caudate nucleus fmm control subjects (solid 
bars) and Huntington's disease (HD) patients (hatched bars). 
Specific binding is expressed as femtmoles per milligram of 
protein. The asterisk denotes A M P A  binding expressed as 
10 ~' fmoll~ng of protein. See legend to F ig  1 for explanation of 
most abbreviations. NNKQ = non-NMDA-, nonkainate-, 
nonquisqualare-sensitive site. 
0.2 for the N N K Q  site). When data were analyzed for 
the effect of postmortem delay on receptor binding, 
no correlation could be determined by regression anal- 
ysis for either control or HD brains in any of the 
assays. When the percentage decreases in binding in 
HD caudate were compared with results of the assays 
showing a significant loss of binding (NMDA, AMPA, 
kainate, glycine, and MK-801) by one-way analysis of 
variance (ANOVA), there was no evidence of a selec- 
tive loss of one receptor subtype compared to the oth- 
ers (p > 0.6). Similar analysis using only brains with 
Vonsattel grade 2 pathology (n = 5) likewise revealed 
no selective loss of receptor binding. 
In order to determine the effect of age on binding, 
multiple regression analysis was performed. In the con- 
trol caudate, age was not correlated with binding for 
NMDA, glycine, MK-801, AMPA, metabotropic, or 
NNKQ site assays. There was, however, a significant 
positive correlation of age with kainate receptor bind- 
ing in control caudate (r2 = 0.577, p < 0.005). In 
contrast to this finding, binding for kainate (r2 = 
0.215, p > 0.2), NMDA, metabotropic, or  NNKQ 
site in HD caudate revealed no significant correlation 
with age, but a significant positive correlation existed 
for age and binding for glycine (r2 = 0.644, p < 
0.005), MK-801 (r2 = 0.398, p < O.OS), and AMPA 
(r2 = 0.536, p < 0.05). In the HD samples, there was 
a statistically significant negative correlation between 
age and grade ( r2  = 0.695, p < 0,001). Therefore, in 
an attempt to determine the relative contribution of 
age and grade to binding in HD caudate, grade was 
Discussion 
Results of previous experiments have suggested that 
EAA-induced neurotoxicity may contribute to the stri- 
atal pathology observed in HD f10-17, 19, 311. Such 
neurotoxicity could result from excessive cortical input 
to striatum, abnormal striatal EAA receptors, excess 
endogenous EAA ligands, or  the abnormal ability of 
striatal cells to cope with normal EAA receptor stimu- 
lation [28]. Quinolinic acid, a tryptophan metabolite, 
is a potent NMDA agonist that occurs normally in the 
human central nervous system. It was recently deter- 
mined that in HD caudate, there is a potential for in- 
creased production of quinolinic acid f 3  11. Young and 
associates [ZS] reported a selective loss of NMDA- 
sensitive receptors in HD putamen and Albin and co- 
workers C321 found a decrease of NMDA receptors 
in a presymptomatic HD brain. These latter findings 
suggested that perhaps NMDA receptors themselves 
are abnormal in HD. The purpose of the present 
study was to define more rigorously the changes in 
EAA receptors in HD using more selective assays. In 
the present study, pharmacologically defined NMDA, 
AMPA, and kainate receptors were decreased to the 
same degree in HD caudate. PCP and glycine sites, 
both associated with the NMDA receptor, were dimin- 
ished similarly. Metabotropic and N N K Q  binding sites 
were not significantly decreased, compared to binding 
sites in control specimens. There was no evidence of 
a selective loss of any single EAA receptor subtype in 
HD caudate. 
Young and associates 1281 reported that several dif- 
ferent receptor types, both glutamatergic and nongluta- 
matergic, showed significant (50-67%) decreases in 
binding in HD. However, NMDA-sensitive glutamate 
binding was decreased even more than was binding to 
other receptors (>$lo%). Since an excitotoxic process 
would be expected to produce cell loss, and a conse- 
quent loss of receptors, the greater loss of the NMDA 
receptors was deemed consistent with the excitotoxic 
process occurring selectively at this class of receptor. 
It is interesting to note that the decreases seen in 
binding to EAA receptors in the present study were 
comparable to the decrease in I3H)TCP binding to the 
PCP receptor reported by Young and associates (ap- 
proximately 50-60% in this study versus 67% in the 
previous one). Furthermore, although the lack of a se- 
lective loss of a receptor subtype is contradictory to the 
results of Young and associates, there are important 
differences between that study and this one. First, the 
previous analysis was carried out using HD putamen 
instead of caudate. A second distinction is that the 
assays for NMDA-sensitive and quisqualate-sensitive 
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binding differ in the two studies. The assay for glu- 
tamate receptors performed by Young and associates 
determined NMDA-sensitive binding by incubating 
the tissue in a solution containing 20 nM I3H)gluta- 
mate and 2.5 pM quisqualate. Nonspecific binding was 
determined with 1 mM glutamate, and specific binding 
was calculated by subtracting the nonspecific binding 
from the total binding under NMDA-sensitive condi- 
tions. A similar method was used to determine quis- 
qualate-sensitive binding, by incubating the tissue in 
the presence of 100 pM NMDA for total binding, and 
adding 2.5 p M  quisqualate for the determination of 
nonspecific binding. This technique of estimating quis- 
qualate binding failed to distinguish between AMPA- 
sensitive quisqualate binding and binding to the meta- 
botropic receptor, and is a measure of binding to both 
sites. The fact that metabotropic receptors were not 
significantly decreased in the present study may in part 
explain the differential decrease in NMDA- versus 
quisqualate-sensitive sites observed in the previous 
study. 
The assays used for binding to NMDA, glycine, 
MK-801, AMPA, metabotropic, and N N K Q  sites 
have been extensively studied in our laboratory, and 
reflect the optimum conditions for detection of specific 
receptor subtypes. Binding of ['H}kainic acid to kai- 
nate receptors has been studied in homogenates of hu- 
man control and HD brains, and suggests the presence 
of high-affinity and low-affinity kainate-binding sites. 
Total C3H}kainate binding was decreased by approxi- 
mately 50% in HD compared to control specimens, 
but high-affinity kainate receptor binding was de- 
creased by 70% in HD striatum 133, 341. For this 
study, total binding (including both high-affinity and 
low-affinity sites) of C3H}kainic acid was measured in 
the striatum. Our finding of a 55% decrease in total 
E3H)kainate binding is in accord with that of these pre- 
vious studies. We are currently investigating the char- 
acteristics of high-affinity ['Hlkainic acid binding in 
human striatum using quantitative in vitro receptor au- 
toradiography. 
We attempted to find a relationship between recep- 
tor binding, age, and pathological grade. The positive 
correlation between age and binding in HD caudate 
for glycine, MK-801, and AMPA may be explained by 
the contribution of pathological grade to the analysis. 
All of the grade 4 HD brains were from patients less 
than 40 years old. There was a statistically signhcant 
negative correlation between age and grade ( r2  = 
0.695, p < 0.001) in the HD brains. The correlation 
between age and grade could explain why the older 
HD patients (with less severe pathology) had appar- 
ently higher amounts of receptor binding. This nega- 
tive correlation of age and grade is in accord with the 
clinical feature of HD that patients who die at an ear- 
lier age have more advanced pathology 1357. When 
pathological grade was treated as a parameter, neither 
grade nor age was consistently a significant determinant 
of binding. Clarification of this issue will require a 
larger number of samples representing each pathologi- 
cal grade, to allow for a more sophisticated statistical 
analysis. 
An intriguing finding in this study is the pattern of 
binding to the NMDA, MK-801, AMPA, kainate, 
rnetabotropic, and N N K Q  receptors in HD caudate. 
While the autoradiograms of control caudates showed 
some heterogeneity of binding throughout the sub- 
stance of the caudate, the HD caudates exhibited more 
pronounced inhomogeneous labeling of receptors, a 
finding noted previously 127, 361. Recent reports of 
synaptophysin and calcineurin immunoreactivity in 
HD caudate demonstrated a similar inhomogeneity 
of cell loss {37, 381. It is known that the striatum is 
a heterogeneous structure composed of regions stain- 
ing lightly for acetylcholinesterase (striosomes) sur- 
rounded by regions with relatively darker staining (ma- 
trix) E37-4 13. The afferent and efferent connections 
of striosomes differ from those of the matrix [42, 431. 
Immunohistochemical evidence would suggest that 
projections from the matrix are initially affected in 
HD. The demonstration by Reiner and associates 1441 
that matrix enkephalinergic projections to the external 
globus pahdus and matrix substance P projections to 
substantia nigra pars reticulata are lost early in HD, 
with relative sparing of substance P-containing pro jec- 
tions to the internal globus pallidus (originating in the 
striosomes), is consistent with this hypothesis. To de- 
termine if the inhomogeneous binding to glutamatergic 
receptors in HD caudates is related to the striosome- 
matrix compartments, acetylcholinesterase staining of 
caudate sections adjacent to those used for autoradiog- 
raphy is being performed in our laboratory. 
The examination of glutamatergic receptor binding 
in control and HD frontal cortex did not demonstrate 
any significant changes, compared to control speci- 
mens. This finding is consistent with those of Young 
and associates, who actually observed a slight increase 
in binding under NMDA- and quisqualate-sensitive 
conditions. These results are also in agreement with 
those of Reynolds and colleagues 1451, who deter- 
mined that there was no significant change in choline 
acetyltransferase or EAA levels in homogenates of ce- 
rebral cortex from demented patients with HD, when 
compared to control specimens. 
The observed losses in caudate of NMDA, AMPA, 
and kainate receptors may simply reflect neuronal cell 
loss. The metabotropic and NNKQ sites showed a less 
pronounced decrease in binding in HD compared to 
NMDA, AMPA, and kainate receptor binding. The 
cellular localization of the metabotropic site within the 
striatum is unknown, whereas NMDA, AMPA, kai- 
nate, and NNKQ receptors are postsynaptic, and 10- 
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cated on the medium-sized spiny neurons 125, 461. 
If the metabotropic receptors are not situated on 
medium-sized spiny neurons, then the changes in re- 
ceptor binding would be less than for the other recep- 
tors. The physiological correlate and significance of 
changes in the N N K Q  binding site are unknown. Fur- 
ther analysis of the discrepancy in binding loss among 
EAA receptors will require characterization of the 
physiology and pharmacology of the metabotropic and 
NNKQ binding sites. 
To delineate the pattern of degeneration in HD, 
further studies are needed to better characterize the 
immunohistochemical features of HD striatum. At- 
tempts to correlate the autoradiographic demonstra- 
tion of inhomogeneities in EAA receptor binding to 
known striosome and/or matrix markers are required 
to determine whether neuronal degeneration in HD 
occurs coincident to an anatomical or neurochemical 
pattern. A striosome-specific marker, when available 
for use in human tissue, could be used with other 
markers to characterize the striosomes and matrix in 
both normal and diseased striatum. By combining auto- 
radiographic binding studies with immunohistochemi- 
cal techniques, there will be a better understanding of 
the pathophysiology of HD. 
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